This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/society/2019/dec/21/cannabis-based-drug-for-epilepsy-to-be-fast-tracked-into-nhs
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Cannabis-based drug for epilepsy to be fast-tracked into NHS | Cannabis-based drug for epilepsy to be fast-tracked into NHS |
| (3 days later) | |
| Epidyolex will be available from 6 January after NHS deal with manufacturer | |
| Cannabis-based medicine is to be fast-tracked into the NHS, allowing thousands of people to be prescribed the drugs, including children with severe epilepsy. | Cannabis-based medicine is to be fast-tracked into the NHS, allowing thousands of people to be prescribed the drugs, including children with severe epilepsy. |
| Last month the NHS struck a deal with the manufacturer GW Pharmaceuticals to bring down the price of Epidyolex, which has been approved by the European medicines agency for use in children over the age of two who suffer from seizures associated with two rare and severe forms of epilepsy – Lennox-Gastaut syndrome (LGS) and Dravet syndrome. | |
| NHS England has said it will speed the process through so that the drugs will be obtainable through doctors from 6 January. | NHS England has said it will speed the process through so that the drugs will be obtainable through doctors from 6 January. |
| Clinical trials have shown the treatment could reduce the number of seizures by up to 40% in some children when used in combination with another drug, Clobazam. It is estimated that 2,000 people a year could benefit. | Clinical trials have shown the treatment could reduce the number of seizures by up to 40% in some children when used in combination with another drug, Clobazam. It is estimated that 2,000 people a year could benefit. |
| The move will not end the calls for cannabis-based medicines to be made easily available on the NHS for people with other conditions. Sativex, GW’s cannabis-based medicine for multiple sclerosis, has been approved only for a limited number of patients because of its high price, to the dismay of campaigners. Others have unsuccessfully campaigned for approval of cannabis medicines to relieve pain. | |
| This year NHS England published a review of when it is safe and appropriate to consider prescribing unlicensed cannabis-based medicines. But it has become apparent that doctors are unwilling to take the responsibility without more evidence on the effects and safety. | This year NHS England published a review of when it is safe and appropriate to consider prescribing unlicensed cannabis-based medicines. But it has become apparent that doctors are unwilling to take the responsibility without more evidence on the effects and safety. |
| The new twice-daily drug is licensed in both the US and Europe. It contains plant-derived, strawberry-flavoured cannabidiol but not THC, which is responsible for the high from smoked cannabis. | The new twice-daily drug is licensed in both the US and Europe. It contains plant-derived, strawberry-flavoured cannabidiol but not THC, which is responsible for the high from smoked cannabis. |
| “The NHS is committed, through the Long Term Plan, to improving the lives of all those affected by rare diseases,” said Simon Stevens, the NHS England chief executive. “Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition. Thousands of people including children will now have access to this treatment, which has the potential to make a real difference.” | “The NHS is committed, through the Long Term Plan, to improving the lives of all those affected by rare diseases,” said Simon Stevens, the NHS England chief executive. “Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition. Thousands of people including children will now have access to this treatment, which has the potential to make a real difference.” |
| • This article was amended on 23 December 2019. An earlier version used the US spelling of Epidiolex throughout, when the product is marketed as Epidyolex in Europe, and incorrectly said that Sativex had been rejected by the NHS. It was approved in November 2019 in England for some cases of spasticity in multiple sclerosis patients. |